Literature DB >> 26830216

Artemisinin protects mice against burn sepsis through inhibiting NLRP3 inflammasome activation.

Huibao Long1, Bincan Xu2, Yanling Luo3, Keqin Luo4.   

Abstract

BACKGROUND: NLRP3 inflammasome activation is recently reported to be linked to the pathogenesis of sepsis. Artemisinin is shown to play beneficial effects in sepsis. However, the impacts of artemisinin on burn sepsis have not been investigated. This study is designed to investigate the role of artemisinin in burn sepsis and the involvement of NLRP3 inflammasome activation.
METHODS: Male BALB/c mice were randomly divided into sham burn, burn, burn sepsis, and artemisinin treated groups. Inflammatory cytokines were measured by enzyme-linked immunosorbent assay. Adhesion molecules and neutrophil infiltration in lung and heart were detected by real-time polymerase chain reaction. Mortality rates were monitored. Artemisinin was added to Raw 264.7 cells that were stimulated with burn sepsis serum in the presence/absence of an inhibitor of NLRP3 inflammasome, 3, 4-methylenedioxy-β-nitrostyrene. Interleukin (IL) 1β and IL-18 messenger RNA expression as well as NLRP3 and caspase 1 protein were measured.
RESULTS: Production of inflammatory cytokines in serum, levels of adhesion molecules and neutrophil infiltration in lung and heart, and mortality rate of burn septic mice were significantly higher than those of control. These effects were attenuated by artemisinin. Artemisinin down-regulated protein levels of NLRP3 and caspase 1 and inhibited the increases of IL-1β and IL-18 messenger RNA expression from Raw 264.7 cells that were stimulated with burn sepsis serum. These effects of artemisinin were not further strengthened in the presence of 4-methylenedioxy-β-nitrostyrene.
CONCLUSION: Artemisinin protects mice from burn sepsis by attenuating the inflammatory response and alleviating inflammatory infiltration in vital organs, likely through inhibiting the activation of NLRP3 inflammasome.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26830216     DOI: 10.1016/j.ajem.2015.12.075

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  6 in total

1.  NLRP3 inflammasome inhibition attenuates sepsis-induced platelet activation and prevents multi-organ injury in cecal-ligation puncture.

Authors:  Denise C Cornelius; Olivia K Travis; Robert W Tramel; Marivee Borges-Rodriguez; Cedar H Baik; Mallory Greer; Chelsea A Giachelli; Geilda A Tardo; Jan M Williams
Journal:  PLoS One       Date:  2020-06-17       Impact factor: 3.240

Review 2.  Inflammasome-Dependent Coagulation Activation in Sepsis.

Authors:  Runliu Wu; Nian Wang; Paul B Comish; Daolin Tang; Rui Kang
Journal:  Front Immunol       Date:  2021-03-16       Impact factor: 7.561

3.  A Pharmacoinformatics Analysis of Artemisinin Targets and de novo Design of Hits for Treating Ulcerative Colitis.

Authors:  Rui Tian; Yufei Li; Xiaofeng Wang; Jiajun Li; Yingqian Li; Shaosheng Bei; Huashan Li
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

4.  Scutellarin Suppresses NLRP3 Inflammasome Activation in Macrophages and Protects Mice against Bacterial Sepsis.

Authors:  Yi Liu; Yan-Yun Jing; Chen-Ying Zeng; Chen-Guang Li; Li-Hui Xu; Liang Yan; Wen-Jing Bai; Qing-Bing Zha; Dong-Yun Ouyang; Xian-Hui He
Journal:  Front Pharmacol       Date:  2018-01-09       Impact factor: 5.810

Review 5.  Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.

Authors:  Yujun Tang; Jiajia Liu; Dingyi Zhang; Zhenghao Xu; Jinjun Ji; Chengping Wen
Journal:  Front Immunol       Date:  2020-07-10       Impact factor: 7.561

6.  NLRP3 inflammasome activation in platelets in response to sepsis.

Authors:  Denise C Cornelius; Cedar H Baik; Olivia K Travis; Dakota L White; Cassandra M Young; W Austin Pierce; Corbin A Shields; Bibek Poudel; Jan M Williams
Journal:  Physiol Rep       Date:  2019-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.